Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Lipocine宣布确认LPCN 1154关键研究的给药方案
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study
On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing
积极的临床研究结果证实了这项关键 PK 研究的 48 小时给药方案
Q2-24 关键研究结果和计划中的 Q4-24 保密协议申请已步入正轨
SALT LAKE CITY, Feb. 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic (PK) study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression (PPD).
盐湖城，2024年2月6日 /PRNewswire/ — 专注于利用其专有平台治疗中枢神经系统（CNS）疾病的生物制药公司Lipocine Inc.（纳斯达克股票代码：LPCN）今天宣布，一项多剂量临床研究的结果证实了即将到来的NDA的关键药代动力学（PK）研究的LPCN 1154 48小时给药方案。LPCN 1154是Lipocine正在开发的一种口服神经类固醇，用于治疗产后抑郁症（PPD）。
PPD is a major depressive disorder with onset either...
PPD 是一种严重...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。